Skip to content
Back to meeting Original
OncoDaily IO· @OncoDailyIO · X·· 3 days agoScore70

ELI-002

Body · original

🧬 AMPLIFY-7P: Primary DFS endpoint not met.

https://oncodaily.com/oncolibrary/immune-oncology/amplify-7p

In 144 patients with resected KRAS-mutated PDAC, camupepimut (ELI-002 7P) vs observation:
⏳ Median DFS: 23.8 vs 21.2 months
📊 HR 0.85; P=0.5329
No significant DFS improvement.
#ESMO2026 #OncoDaily #ESMO26

109 views · 1 like · 0 reposts · 0 replies

Conference abstracts
7Pmatched by Proffered paper 1: Gastrointestinal tumour, upper digestive

Proffered paper 1: Gastrointestinal tumour, upper digestive

https://esmocongress.esmo.org

Source: OncoDaily IO · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.